Go Pro
OTCMKTS:BVNRY

Bavarian Nordic Q4 2025 Earnings Report

Bavarian Nordic logo
$11.09 +0.05 (+0.49%)
As of 09/28/2026 09:45 AM Eastern

Bavarian Nordic EPS Results

Actual EPS
-$0.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bavarian Nordic Revenue Results

Actual Revenue
$226.16 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bavarian Nordic Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Bavarian Nordic Earnings Headlines

Bavarian Nordic (OTCMKTS:BVNRY) Shares Gap Up - Still a Buy?
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
Bavarian Nordic AS ADR BVNRY
See More Bavarian Nordic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bavarian Nordic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bavarian Nordic and other key companies, straight to your email.

About Bavarian Nordic

Bavarian Nordic (OTCMKTS:BVNRY) A/S (OTCMKTS:BVNRY) is a Danish biotechnology company that develops, manufactures and commercializes vaccines for infectious diseases. The company serves government agencies, military organizations, healthcare providers and travelers, with products distributed across Europe, North America and other international markets.

Its best-known product is JYNNEOS, also marketed as IMVAMUNE or IMVANEX in certain regions, a non-replicating smallpox and mpox vaccine. Bavarian Nordic also offers vaccines for rabies and tick-borne encephalitis, including RabAvert and Rabipur for rabies prevention and Encepur for protection against tick-borne encephalitis. Its portfolio includes vaccines used in routine, travel and outbreak-response settings.

Founded in 1994 and headquartered in Hellerup, Denmark, Bavarian Nordic has developed specialized vaccine production capabilities and works with public-sector customers on preparedness for infectious disease threats. The company also conducts research and development aimed at expanding its vaccine portfolio and addressing additional unmet needs in infectious disease prevention.

View Bavarian Nordic Profile